All products are for research use only. Not for human consumption.
Growth hormone secretagogues are synthetic peptides that engage the ghrelin receptor (GHS-R1a) to stimulate GH release in preclinical models. While they are often grouped together, the three most-studied compounds — ipamorelin, GHRP-2, and GHRP-6 — differ meaningfully in their off-target effects on cortisol, prolactin, and appetite-related signaling.
For researchers, these differences are not minor footnotes. They determine which variables can be held constant in an experimental design. All compounds discussed are for research use only.
Ipamorelin is a pentapeptide that engages the ghrelin receptor with high selectivity. In preclinical literature, it is the secretagogue most consistently described as producing GH release without measurable elevations in cortisol or prolactin at standard research doses.
Studies published in journals including European Journal of Endocrinology have characterized ipamorelin's selectivity profile, making it the secretagogue of choice when researchers need a clean GH response without confounding effects on the HPA axis.
GHRP-2 is a hexapeptide ghrelin receptor agonist that has been studied for longer than ipamorelin. It produces a more robust GH response on a milligram-for-milligram basis, but at the cost of measurable effects on cortisol and prolactin in preclinical models.
The trade-off is potency for selectivity. Researchers who want maximum GH stimulation and are not specifically studying the HPA axis may prefer GHRP-2. Those measuring stress hormones or prolactin-related endpoints would generally avoid it.
GHRP-6 is the original ghrelin mimetic in this family. Like GHRP-2, it engages the ghrelin receptor but with the additional pronounced effect of stimulating appetite — an effect that closely mirrors endogenous ghrelin biology.
This appetite effect is sometimes the point. Researchers studying ghrelin's central role in feeding behavior may specifically choose GHRP-6 because it captures both the somatotropic and orexigenic dimensions of ghrelin signaling. In studies where appetite is a confounder, GHRP-6 is generally avoided.
The right compound depends entirely on what variables the researcher needs to control. A study examining IGF-1 dynamics that should not be confounded by elevated cortisol would point to ipamorelin. A study examining ghrelin's role in feeding would point to GHRP-6. A study optimizing for raw GH output where HPA effects are not part of the question may favor GHRP-2.
All three secretagogues are commonly studied alongside GHRH analogs such as CJC-1295 (with or without DAC) or sermorelin. The two pathways are synergistic in preclinical models, and combination protocols are common in published research.
Because secretagogue research often involves precise dose-response work, peptide purity is critical. Researchers should look for HPLC purity of 98% or higher, with mass spectrometry confirmation and a documented Certificate of Analysis from the supplier.
None of the three compounds is approved for human therapeutic use. All available data come from in vitro and animal studies, and these peptides are sold strictly for laboratory research purposes.
Ipamorelin is consistently described in preclinical literature as the most selective of the three, with minimal off-target effects on cortisol, prolactin, and appetite signaling.
Because of its pronounced appetite-stimulating effect, GHRP-6 is useful for studies examining the orexigenic dimensions of ghrelin receptor signaling rather than GH release in isolation.
None of these compounds is approved for human use. They are intended strictly for laboratory research only.
Disclaimer: This article is provided for educational and informational purposes only. It does not constitute medical advice. All products referenced are intended strictly for laboratory research use only and are not approved for human consumption.
52 compounds. 99%+ purity. Certificate of Analysis included with every order.